McKesson Buys Home Infusion Company Option Care for $5.8B

NEW YORK—McKesson Corporation and the private equity company CD&R have agreed to purchase home infusion provider Option Care Health, Inc. for roughly $5.8 billion, the companies announced Oct. 6. At the closing of the transaction, CD&R will hold a majority ownership interest and McKesson will hold a minority ownership interest. Option Care Health will remain a separate company led by its own management team.

The purchase price is based on a sale at $32.05 per share. The transaction is expected to close in the first half of 2027 and will take Option Care private.

“For more than 45 years, Option Care Health has helped transform the way infusion therapy is delivered, led by our team members’ unwavering commitment to providing extraordinary care to patients,” said Option Care CEO John C. Rademacher. “We will continue to enhance our platform and deepen our partnerships with hospitals and health systems, physicians, payers, and biopharma manufacturers. We are thrilled to have the support of CD&R and McKesson, empowering us to continue investing strategically and accelerate the pace of our advanced technology deployment to improve clinical outcomes and reduce the total cost of care. Both firms understand our business and the healthcare industry, and have proven track records of fostering growth for some of the largest and fastest-growing healthcare service businesses globally.”

“Option Care Health has shown what is possible when high-quality infusion therapy is delivered where patients are most comfortable: at home and in their communities,” said CD&R Partner Sarah Kim. “We look forward to supporting Option Care Health’s proven management team, together with McKesson and applying CD&R’s deep experience in healthcare services to help Option Care Health bring specialized therapies to more patients across the country.”

“This investment represents an important opportunity that aligns with McKesson’s long-term strategy to expand access and affordability to innovative therapies across the care continuum,” said McKesson Chair and CEO Brian Tyler. “As these therapies continue to grow in importance and their delivery becomes increasingly complex, McKesson is focused on investing in areas where our capabilities can help improve access and advance care in lower-cost community settings, at or closer to home. Option Care Health’s clinical model and national infusion footprint across home and ambulatory sites are well aligned with those priorities, and the company is well positioned for continued growth. As a strategic investor, we look forward to bringing McKesson’s experience and expertise in specialty pharmaceuticals to support Option Care Health’s strategy of broadening access to complex therapies and enabling care delivery in lower-cost settings, while creating long-term value for stakeholders.”

McKesson said the purchase helps it achieve its strategic objectives, including continued innovation in specialty, rare and orphan therapies and meeting the increasing need for alternate infusion services. “Option Care Health’s home and ambulatory infusion capabilities help patients access complex therapies outside traditional care settings, aligning with McKesson’s focus to allow accessible and affordable high-quality care to patients,” the company said in a release.

Option Care Health will continue to operate as usual, with the same commitment to its patients, providers, employees, and partners.